tiprankstipranks
Spectral Medical Nears Tigris Trial Completion
Company Announcements

Spectral Medical Nears Tigris Trial Completion

Story Highlights

Spectral Medical (TSE:EDT) has released an update.

Pick the best stocks and maximize your portfolio:

Spectral Medical Inc. has announced robust patient enrollment in the Tigris trial for July, maintaining a strong performance from the beginning of the year and marking a record month equal to June’s achievement. The trial, which is close to full enrollment with just 25 patients remaining, is on track to potentially complete by December 2024. This Phase 3 study is critical for the company’s innovative sepsis treatment device, PMX, which has already seen significant use globally and has received Breakthrough Device Designation from the FDA.

For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskSpectral Medical Advances Amid Tigris Trial Challenges
TipRanks Canadian Auto-Generated NewsdeskSpectral Medical Advances with Tigris Trial Progress
TipRanks Canadian Auto-Generated NewsdeskSpectral Medical Nears Completion of Tigris Trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App